How have ONC shares performed in 2024?

Oncimmune's stock was trading at GBX 25.20 at the beginning of the year. Since then, ONC stock has increased by 9.5% and is now trading at GBX 27.60. View the best growth stocks for 2024 here .

How were Oncimmune's earnings last quarter?

Oncimmune Holdings plc (LON:ONC) issued its quarterly earnings data on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The business earned $0.08 million during the quarter. Oncimmune had a negative trailing twelve-month return on equity of 760.96% and a net margin of 356.25%.

What other stocks do shareholders of Oncimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM) , Digi International (DGII) , SeaChange International (SEAC) , SMTC (SMTX) , Axsome Therapeutics (AXSM) , Chimerix (CMRX) and Constellation Pharmaceuticals (CNST) .

How do I buy shares of Oncimmune?

Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:ONC

Oncimmune (ONC) Share Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free ONC Stock Alerts

GBX 27.60

-1.50 (-5.15%)

(As of 04/19/2024 ET)

Compare

Today's Range: 27.48
▼
29
50-Day Range: 16.80
▼
30.42
52-Week Range: 13
▼
45

Volume: 62,630 shs
Average Volume: 76,900 shs
Market Capitalization: £20.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Headlines Insider Trades

Get Oncimmune alerts:

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Oncimmune Stock (LON:ONC)

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

ONC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONC Stock News Headlines

March 19, 2024 | wsj.com

Oncimmune Holdings PLC

March 2, 2024 | finance.yahoo.com

Oncimmune Holdings Full Year 2023 Earnings: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

April 19, 2024 | Banyan Hill Publishing (Ad)

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

February 15, 2024 | reuters.com

Cancer test firm Freenome raises $254 mln in fresh funding

February 14, 2024 | msn.com

Activist investor Kelso gains board seats at The Works as it tries to enhance shareholder value

December 2, 2023 | proactiveinvestors.com.au

Oncimmune seeing commercial traction as it inks new deals with big pharma companies

September 26, 2023 | yahoo.com

The Unique Use of Liquid Biopsy

August 1, 2023 | marketwatch.com

Oncimmune's Acting CEO Ron Kirschner Steps Down, Takes COO Role; Gouldstone Starts as CEO

April 19, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

July 14, 2023 | marketwatch.com

Oncimmune Shares Fall As Company Lowers FY 2022 Revenue Result

July 12, 2023 | lse.co.uk

Oncimmune names chief executive successor, while finance chief leaves

July 12, 2023 | marketwatch.com

Oncimmune Holdings Appoints Martin Gouldstone CEO; CFO Matthew Hall to Step Down

June 23, 2023 | lse.co.uk

Oncimmune Holdings shakes up leadership and unveils new growth plan

June 23, 2023 | marketwatch.com

Oncimmune CEO Adam Hill to Step Down; Sees Tough End to FY 2023

May 31, 2023 | lse.co.uk

Oncimmune shares plummet as interim revenue falls by fifth

May 31, 2023 | marketwatch.com

Oncimmune Shares Fall on 1H Pretax Loss

May 22, 2023 | lse.co.uk

Oncimmune sells two subsidiaries to Freenome for GBP13 million

May 22, 2023 | markets.businessinsider.com

FREENOME ACQUIRES GLOBAL IMMUNODIAGNOSTICS DEVELOPER ONCIMMUNE LTD

May 22, 2023 | marketwatch.com

Oncimmune Eases Going-Concern Risk With Sale of Two Subsidiaries for GBP13 Mln

April 28, 2023 | marketwatch.com

The Comprehensive Guide to the Cancer Biopsy Market: Trends and Revenue Forecast with predicted CAGR of 4.2% from 2023-2030

April 22, 2023 | marketwatch.com

Cancer Biopsy Market Outlook by 2031

April 12, 2023 | finance.yahoo.com

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

February 28, 2023 | proactiveinvestors.com

Oncimmune delivering top-line growth

February 27, 2023 | marketwatch.com

Oncimmune Shares Fall After Going Concern Warning, Pretax Loss

February 20, 2023 | lse.co.uk

CORRECT: Oncimmune works with Siemens Healthineers on cancer therapy

January 25, 2023 | theguardian.com

Richard Sharp: BBC chair was shareholder in firm awarded £600k while he was a No 10 adviser

January 2, 2023 | finance.yahoo.com

Investors in Oncimmune Holdings (LON:ONC) have unfortunately lost 67% over the last year

See More Headlines

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:ONC
CUSIP: N/A
CIK: N/A
Web: oncimmune.com
Phone: +44-115-8231869
Fax: N/A
Employees: 52
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 32.51
P/E Growth: N/A
Net Income: £-6,150,000.00
Net Margins: 356.25%
Pretax Margin: N/A
Return on Equity: -760.96%
Return on Assets: -26.38%

Debt

Debt-to-Equity Ratio: 806.85
Current Ratio: 3.91
Quick Ratio: 0.63

Sales & Book Value

Annual Sales: £1.15 million
Price / Sales: 18.05
Cash Flow: GBX 2.34 per share
Price / Cash Flow: 11.96
Book Value: GBX 1 per share
Price / Book: 28.00

Miscellaneous

Outstanding Shares: 74,140,000
Free Float: N/A
Market Cap: £20.76 million
Optionable: Not Optionable
Beta: 1.12

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Martin John Gouldstone (Age 58)
CEO & Director
Mr. Martin Hudson
Finance Director
Mr. Ron Kirschner (Age 45)
COO, General Counsel & Company Secretary
Prof. Tariq Sethi B.Sc.
FRCP, M.A., M.D., Ph.D., Chief Scientific Officer
Ms. Cléa Rosenfeld
Head of Investor Relations
Mr. Maarten Brusse
Chief Commercial Officer of Asia

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed in 2024?: Oncimmune's stock was trading at GBX 25.20 at the beginning of the year. Since then, ONC stock has increased by 9.5% and is now trading at GBX 27.60.
View the best growth stocks for 2024 here.
How were Oncimmune's earnings last quarter?: Oncimmune Holdings plc (LON:ONC) issued its quarterly earnings data on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The business earned $0.08 million during the quarter. Oncimmune had a negative trailing twelve-month return on equity of 760.96% and a net margin of 356.25%.
What other stocks do shareholders of Oncimmune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST).
How do I buy shares of Oncimmune?: Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ONC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial